RAF1 and neoplasm: Sorafenib is a molecule capable of multi - level kinase inhibition, with particular activity against VEGFR and RAF (the RAF/MEK/ERK pathway), a major pathway involved in the proliferation of tumor cells [9], opposing c -RAF, B -Raf, c- KIT, FLT3, Platelet-derived growth factor receptor (PDGFR) α and β, vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3, and various other kinases [10], giving this medicine both pro - apoptotic properties and anti-angiogenic effects.